Evorel Oestradiol Patch

What it is:

Evorel is a transdermal oestrogen patch manufactured by Janssen-Cilag and one of the most commonly prescribed HRT products in the UK. The active ingredient is 17-beta oestradiol, chemically identical to the oestrogen produced naturally by the ovaries. [1]

What do the guidelines say?

Every major menopause guideline supports transdermal estradiol as a first-line option. NICE NG23 (2024) recommends HRT for vasomotor symptoms and specifically favours transdermal over oral HRT for women at increased blood clot risk, including those with a BMI over 30 [1]. The BMS/WHC consensus (2020, updated 2025) states transdermal estradiol is unlikely to increase blood clot or stroke risk above baseline [2]. NAMS (2022) confirms HRT is the most effective treatment for vasomotor symptoms, with transdermal routes potentially reducing clot and stroke risk [3]. The IMS 2024 White Paper supports 25-50mcg patches for symptom relief and bone protection [4]. No guideline names Evorel specifically; they refer to the product category.

For GSM (vaginal dryness, painful sex), NICE recommends local vaginal oestrogen, not systemic patches, as first-line, even for women already on systemic HRT [1]. For mood, NICE says to consider HRT for depressive symptoms arising alongside other menopause symptoms, but not as treatment for diagnosed depression [1].

What does the evidence say?

Vasomotor symptoms (hot flushes): Strong evidence. A Cochrane review (2016, 23 RCTs, 5,779 women) found bioidentical estradiol patches significantly reduced hot flush frequency versus placebo [5]. A systematic review (Corbelli 2015, 9 RCTs) confirmed low-dose transdermal estradiol at any dose was more effective than placebo [6]. A network meta-analysis (Kovacs 2016, 46 studies) confirmed effectiveness across all transdermal estradiol doses from 14-50mcg [7]. An umbrella review (2021, 60 systematic reviews) confirmed HRT reduced vasomotor symptom frequency by 57% and severity by 71% in RCTs [8].

Sleep: Moderate evidence. A meta-analysis (Pan 2022, 15 RCTs) found HRT improved sleep, with transdermal 17-beta-estradiol showing the most benefit [9]. An RCT (Geiger 2019, 172 women) found transdermal estradiol reduced time to fall asleep and awakenings, partly independent of hot flush improvement [10]. However, an earlier meta-analysis (Cintron 2017) suggested the benefit was mainly linked to reducing night sweats, with uncertain effects in women without vasomotor symptoms [11].

Mood: Promising but limited. One well-designed RCT (Gordon 2018, 172 women, JAMA Psychiatry) found 17.3% of women on transdermal estradiol developed depressive symptoms over 12 months versus 32.3% on placebo [12]. But this is essentially one trial, and guidelines remain cautious.

GSM: Systemic patches are not the recommended approach. Guidelines consistently recommend local vaginal oestrogen for vaginal dryness and related symptoms, sometimes alongside systemic HRT. Claims that Evorel addresses GSM as a primary benefit slightly overreach the evidence for this specific delivery route.

Blood clot risk: The claim of lower risk versus oral HRT is supported by a meta-analysis of observational studies cited in the BMS consensus [2], but no large RCTs have directly compared clot risk between routes.

‍

‍

References

[1] NICE. Menopause: identification and management (NG23). Updated November 2024. Available at: https://www.nice.org.uk/guidance/ng23. No PMID (clinical guideline).

[2] British Menopause Society & Women's Health Concern. Recommendations on hormone replacement therapy in menopausal women. 2020 (updated 2025). Available at: https://thebms.org.uk/publications/consensus-statements/. No PMID (clinical guideline).

[3] Faubion S et al. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29(7):767-794. PMID: 35797481. https://pubmed.ncbi.nlm.nih.gov/35797481/

[4] International Menopause Society. Menopause and MHT in 2024: addressing the key controversies. Climacteric 2024;27(5):441-457. Available at: https://www.tandfonline.com/doi/full/10.1080/13697137.2024.2394950.

[5] Gaudard A et al. Bioidentical hormones for women with vasomotor symptoms. Cochrane Database Syst Rev 2016;(8):CD010407. PMID: 27479272. https://pubmed.ncbi.nlm.nih.gov/27479272/

[6] Corbelli J et al. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review. Menopause 2015;22(1):114-121. PMID: 24977458. https://pubmed.ncbi.nlm.nih.gov/24977458/

[7] Kovacs G et al. Comparison of efficacy and local tolerability of estradiol metered-dose transdermal spray to estradiol patch in a network meta-analysis. Climacteric 2016;19(5):488-495. PMID: 27593417. https://pubmed.ncbi.nlm.nih.gov/27593417/

[8] Nguyen T et al. Menopausal hormone therapy and women's health: an umbrella review. PLoS Medicine 2021;18(8):e1003731. Available at: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003731.

[9] Pan Z et al. Different regimens of menopausal hormone therapy for improving sleep quality: a systematic review and meta-analysis. Menopause 2022;29(5):627-635. Available at: https://journals.lww.com/menopausejournal/fulltext/2022/05000/different_regimens_of_menopausal_hormone_therapy.17.aspx.

[10] Geiger P et al. Effects of perimenopausal transdermal estradiol on self-reported sleep. Menopause 2019;26(11):1318-1323. PMID: 31688579. https://pubmed.ncbi.nlm.nih.gov/31688579/

[11] Cintron D et al. Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis. Endocrine 2017;55:702-711. PMID: 27515805. https://pubmed.ncbi.nlm.nih.gov/27515805/

[12] Gordon J et al. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiatry 2018;75(2):149-157. PMID: 29322164. https://pubmed.ncbi.nlm.nih.gov/29322164/

‍